Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Improvement of treatment efficacy and decreased side effects through tumor-targeted drug delivery would be desirable. By panning with a phage-displayed cyclic random peptide library we selected a peptide with strong affinity for RMS in vitro and in vivo. The peptide minimal binding motif Arg-X-(Arg/Lys)(Arg/Lys) identified by alanine-scan, suggested the target receptor to be a proprotein convertase (PC). Expression profiling of all PCs in RMS biopsies and cell lines revealed consistent high expression levels for the membrane-bound furin and PC7. Direct binding of RMS-P3 peptide to furin was demonstrated by affinity chromatography and supported by activity and colocalization studies. Treatment of RMS in mice with doxorubicin coupled to the targeting peptide resulted in a two-fold increase in therapeutic efficacy compared to doxorubicin treatment alone. Our findings indicate surface-furin binding as novel mechanism for therapeutic cell penetration which needs to be further investigated. Furthermore, this work demonstrates that specific targeting of membrane-bound furin in tumors is possible for and suggests that RMS and other tumors might benefit from proprotein convertases targeted drug delivery.
Hajdin
Katarina
K
Department of Oncology, University Children's Hospital Zurich, Zurich, Switzerland.
D'Alessandro
Valentina
V
Niggli
Felix K
FK
Schäfer
Beat W
BW
Bernasconi
Michele
M
D020816:Amino Acid Motifs; D000595:Amino Acid Sequence; D000818:Animals; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D016650:Fluorescein-5-isothiocyanate / Q000378:metabolism; D045683:Furin / Q000378:metabolism*; D006056:Golgi Apparatus / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D019151:Peptide Library; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000378:metabolism; D015203:Reproducibility of Results; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
D019151:Peptide Library; D010455:Peptides; D011956:Receptors, Cell Surface; D004317:Doxorubicin; D045683:Furin; D016650:Fluorescein-5-isothiocyanate
Br J Cancer. 1997;75(10):1509-14
9166946
Biopolymers. 2002;66(3):184-99
12385037
Cancer Cell. 2003 Nov;4(5):393-403
14667506
Expert Opin Ther Targets. 2008 Oct;12(10):1289-300
18781827
J Neurochem. 2004 Dec;91(6):1275-83
15584904
Mol Cancer. 2009 Sep 08;8:73
19737405
Oncologist. 2005 Aug;10(7):518-27
16079319
J Biol Chem. 2009 Oct 2;284(40):27157-66
19651771
Mol Carcinog. 2001 Aug;31(4):224-32
11536372
J Clin Invest. 2008 Jan;118(1):352-63
18064302
Int J Cancer. 2009 May 1;124(9):2026-32
19123480
Am J Pathol. 2003 Feb;162(2):439-47
12547702
Int J Biochem Cell Biol. 2010 Jun;42(6):987-95
20197107
J R Soc Med. 2005 Apr;98(4):146-52
15805554
Biochem Biophys Res Commun. 2004 Aug 27;321(3):531-8
15358140
Am J Pathol. 2001 Jan;158(1):305-16
11141505
FEBS Lett. 1993 Aug 9;328(1-2):25-9
8344430
Cancer Res. 2004 Apr 15;64(8):2853-7
15087403
Nature. 2004 Jun 10;429(6992):629-35
15190345
Cancer Res. 2008 Sep 1;68(17):7210-8
18757437
Biochem J. 1997 Nov 1;327 ( Pt 3):625-35
9599222
J Mol Endocrinol. 2000 Feb;24(1):1-22
10656993
Clin Cancer Res. 2002 Jun;8(6):1740-6
12060611
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7293-8
9636142
Biochem Soc Trans. 2007 Aug;35(Pt 4):780-3
17635147
FEBS Lett. 2003 Nov 20;554(3):275-83
14623079
Cancer Res. 2004 Aug 15;64(16):5539-45
15313887
Nat Biotechnol. 2005 Sep;23(9):1147-57
16151408
Biochem J. 2003 Jul 15;373(Pt 2):475-84
12691605
J Biol Chem. 1993 Jun 25;268(18):13406-13
8099909
Trends Pharmacol Sci. 2005 Jun;26(6):294-301
15925704
J Biol Chem. 1995 Nov 3;270(44):26565-9
7592877
Nat Rev Mol Cell Biol. 2002 Oct;3(10):753-66
12360192
J Biol Chem. 2001 Aug 17;276(33):30686-93
11402025
J Control Release. 2003 Aug 28;91(1-2):183-6
12932650
Brain Res. 1999 Nov 27;848(1-2):45-62
10701998
Cancer Res. 2007 Oct 1;67(19):9030-4
17909005
Mol Carcinog. 2005 Nov;44(3):151-61
16167351
Am J Pathol. 2002 Jun;160(6):1921-35
12057895
J Cell Biol. 2003 Nov 24;163(4):871-8
14638862
PLoS One. 2009 Nov 26;4(11):e7700
19956642
Cancer Res. 2008 Sep 1;68(17):6922-31
18757406
FASEB J. 2007 Apr;21(4):1088-98
17242158
Future Oncol. 2009 Nov;5(9):1449-75
19903072
Cancer Cell. 2009 Dec 8;16(6):510-20
19962669
Crit Rev Oncol Hematol. 2005 Apr;54(1):11-29
15780905
Nat Med. 2002 Jul;8(7):751-5
12053175
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62
19805273
Biopolymers. 2006;84(3):241-9
16333858
J Biol Chem. 1996 Nov 29;271(48):30442-50
8940009
J Biol Chem. 2008 Apr 25;283(17):11752-62
18292083
Mol Pharm. 2007 Sep-Oct;4(5):631-51
17880166
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10326-31
11517338
Br J Cancer. 2000 Mar;82(6):1239-45
10735512
Biochem Soc Trans. 2004 Jun;32(Pt3):397-402
15157146
Blood. 2002 Nov 15;100(10):3578-87
12411321
J Clin Invest. 2003 Jun;111(11):1723-32
12782675